This article contains information concerning the aspects of pharmacokinetics and pharmacodynamics of dihydropyridine calcium antagonists. The authors have discussed the evidence-based amlodipine treatment of arterial hypertension, ischemic heart disease and chronic heart failure. The authors present the comparison of the efficacy, safety and application characteristics of the different dihydropyridine calcium antagonists that can be used in specific clinical cases
Calcium channel blockers, despite former debates on side-effects and safety-problems, still hold an ...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
WOS: 000183228900011PubMed ID: 12803737Background: Hypertension is one of the most important causes ...
Findings of the main clinical trials of amlodipine in the treatment of arterial hypertension and pre...
The article discusses the problem of using calcium antagonists in clinical practice. Physicians' jud...
Objectives: Hypertension is well established as a major risk factor for cardiovascular disease. Alth...
Abstract Hypertension is the leading cause of death worldwide, affecting 1.4 billion people. Treatme...
Amlodipine – a third generation dihydropyridine calcium antagonist H.-M. Steffen Amlodipine, a third...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
This paper summarizes the pharmacological properties of calcium channel blockers (CCBs), their estab...
Calcium antagonists are one of the first line medication in management of hypertension. They inhibit...
The calcium channel antagonists are not an homogeneous group. From both pharmacological and clinical...
The article discusses the problem of using calcium antagonists in clinical practice. Taking into acc...
Calcium channel blockers, despite former debates on side-effects and safety-problems, still hold an ...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
WOS: 000183228900011PubMed ID: 12803737Background: Hypertension is one of the most important causes ...
Findings of the main clinical trials of amlodipine in the treatment of arterial hypertension and pre...
The article discusses the problem of using calcium antagonists in clinical practice. Physicians' jud...
Objectives: Hypertension is well established as a major risk factor for cardiovascular disease. Alth...
Abstract Hypertension is the leading cause of death worldwide, affecting 1.4 billion people. Treatme...
Amlodipine – a third generation dihydropyridine calcium antagonist H.-M. Steffen Amlodipine, a third...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
This paper summarizes the pharmacological properties of calcium channel blockers (CCBs), their estab...
Calcium antagonists are one of the first line medication in management of hypertension. They inhibit...
The calcium channel antagonists are not an homogeneous group. From both pharmacological and clinical...
The article discusses the problem of using calcium antagonists in clinical practice. Taking into acc...
Calcium channel blockers, despite former debates on side-effects and safety-problems, still hold an ...
Background: Hypertension is one of the most important causes of cardiovascular disease, and treatmen...
WOS: 000183228900011PubMed ID: 12803737Background: Hypertension is one of the most important causes ...